U.S. STOCKS ON THE MOVE-Teradyne, Keysight Technologies, Ametek
U.S. STOCKS ON THE MOVE-HeartBeam, Teradyne, Keysight Technologies
PepGen falls on clinical hold notice from FDA for mid-stage muscle disorder trial
Brief: Pepgen Announces Clinical Hold In The U.S. On Ind Application To Initiate Connect2-Edo51 Phase 2 Study
PepGen Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: PepGen Q3 Operating Expenses USD 23.171 Million
PepGen Inc expected to post a loss of 87 cents a share - Earnings Preview
Brief: Pepgen Inc - Adopted Resolution As Of Sept 18, Decreasing Size Of Board From Seven Directors To Six Directors
Brief: PepGen Announces Christopher Ashton To Retire From Its Board Of Directors
Brief: Pepgen Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) To Newly Appointed Executive Vice President, Research & Development
Brief: PepGen Q2 Net Income USD -28.335 Million
Brief: Pepgen Announces Positive Data From Ongoing Phase 2 Trial For Treatment Of Duchenne Muscular Dystrophy
Brief: PepGen Files For Mixed Shelf Offering Of Up To $250 Million
Brief: PepGen Q1 Operating Income USD -19.798 Million
Brief: Pepgen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For Pgn-Edo51 To Treat A Muscle Disorder
Brief: PepGen Reports Fourth Quarter And Full Year 2023 Results
Brief: PepGen Q4 Net Income USD -19.495 Million
Stifel says Avidity trial update is 'positive' for muscle wasting treatments
Brief: PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency